NovaBay Pharmaceuticals (NBY) 10-Q 7 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 03, 2018
Document Information [Line Items]
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Central Index Key	1,389,545
Trading Symbol	nby
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		17,089,304
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 6,833	$ 3,199
Accounts receivable, net of allowance for doubtful accounts ($11 and $13 at June 30, 2018 and December 31, 2017, respectively)	2,024	3,629
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $138 and $140 at June 30, 2018 and December 31, 2017, respectively	317	504
Prepaid expenses and other current assets	1,598	1,663
Total current assets	10,772	8,995
Property and equipment, net	351	471
Other assets	582	613
TOTAL ASSETS	11,705	10,079
Current liabilities:
Accounts payable	329	466
Accrued liabilities	2,665	1,672
Deferred revenue	62	75
Total current liabilities	3,056	4,979
Deferred revenues - non-current		534
Deferred rent	237	286
Warrant liability	785	1,489
Other liabilities	198	197
Total liabilities	4,276	7,485
Stockholders' equity:
Preferred stock: 5,000 shares authorized; none outstanding at June 30, 2018 and December 31, 2017	0	0
Common stock, $0.01 par value; 50,000 and 240,000 shares authorized at June 30, 2018 and December 31, 2017, respectively; 17,089 and 15,385 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	171	154
Additional paid-in capital	119,433	113,514
Accumulated deficit	(112,175)	(111,074)
Total stockholders' equity	7,429	2,594
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 11,705	$ 10,079

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 11	$ 13
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 138	$ 140
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	240,000,000
Common stock, shares issued (in shares)	17,089,000	15,385,000
Common stock, shares outstanding (in shares)	17,089,000	15,385,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Total sales, net	$ 2,794	$ 4,122	$ 5,741	$ 7,823
Product cost of goods sold	479	698	730	1,286
Gross profit	2,315	3,424	5,011	6,537
Research and development	61	70	107	132
Sales and marketing	2,977	3,376	6,373	7,116
General and administrative	1,360	1,735	2,982	4,823
Total operating expenses	4,398	5,181	9,462	12,071
Operating Loss	(2,083)	(1,757)	(4,451)	(5,534)
Non-cash gain (loss) on changes in fair value of warrant liability	490	15	704	(220)
Other income (expense), net	(5)	(4)	(9)	(6)
Loss before provision for income taxes	(1,588)	(1,738)	(3,738)	(5,748)
Provision for income tax	(1)		(1)	(1)
Net loss and comprehensive loss	$ (1,589)	$ (1,738)	$ (3,739)	$ (5,749)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.09)	$ (0.11)	$ (0.22)	$ (0.38)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.12)	$ (0.11)	$ (0.26)	$ (0.38)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock
Basic (in shares)	17,089	15,308	16,750	15,296
Diluted (in shares)	17,292	15,308	16,985	15,296
Product [Member]
Total sales, net	$ 2,794	$ 4,094	$ 5,728	$ 7,788
Product and Service, Other [Member]
Total sales, net		$ 28	$ 13	$ 35

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net loss	$ (3,739,000)	$ (5,749,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	127,000	36,000
Stock option modification expense	77,000
Non-cash (gain) loss on change in fair value of warrant liability	(704,000)	220,000
Changes in operating assets and liabilities:
Decrease (Increase) in Accounts receivable	2,134,000	(1,480,000)
Decrease in Inventory	160,000	200,000
Decrease in Prepaid expenses and other assets	64,000	1,004,000
Decrease (Increase) in Other assets long-term	33,000	(101,000)
(Decrease) Increase in Accounts payable and accrued liabilities	(327,000)	390,000
(Decrease) Increase in Deferred rent	(32,000)	48,000
Increase (Decrease) in Deferred revenue	(13,000)	118,000
Net cash used in operating activities	(1,957,000)	(3,625,000)
Investing activities:
Purchases of property and equipment	(5,000)	(155,000)
Net cash used in investing activities	(5,000)	(155,000)
Financing activities:
Proceeds from common stock issuances, net	5,585,000
Proceeds from exercise of options, net	11,000	0
Proceeds from stock options & RSUs for taxes	1,000
Settlement of restricted stock for tax withholding		(48,000)
Exercise of warrants, net		38,000
Net cash provided by (used in) financing activities	5,597,000	(10,000)
Net increase (decrease) in cash and cash equivalents	3,635,000	(3,790,000)
Cash, cash equivalents and restricted cash, beginning of period	3,673,000	9,986,000
Cash, cash equivalents and restricted cash, end of period	7,308,000	6,196,000
Supplemental disclosure of non cash information
Cumulative effect of adoption of new accounting standard	2,638,000
Stock issued to consultants for services, included in accounts payable and accrued liabilities		1,000
Fixed asset purchases, included in accounts payable and accrued liabilities	1,000
Equity transferred to warrant liability		58,000
Proceeds from stock options and restricted stock for taxes, in accounts payable and accrued liabilities	1,000
Employees and Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	250,000	1,600,000
Nonemployees [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	13,000	89,000
Severance Paid in Restricted Stock Units to Non-employees [Member]
Supplemental disclosure of non cash information
Severance paid in RSUs to non-employee		$ 69,000

Note 1 - Organization

Note 1 - Organization	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two ® ® ® ® ® The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, Effective December 18, 2015, 1 25 11 Liquidity Based primarily on the funds available at June 30, 2018, April 2019. 2018 2018 may 1 2 3 one 4 may 1 3 one one not may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. Prior period amounts in the accompanying consolidated statements of operations and comprehensive loss have also been reclassified to conform to current period presentation. The reclassifications did not Additionally, prior period amounts in the accompanying consolidated statements of cash flow have also been reclassified to conform to current period presentation. The reclassifications did not Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three June 30, 2018, December 31, 2017, two Beginning fiscal 2018, No. 2016 18, Statement of Cash Flows (Topic 230 $474 December 31, 2017, $475 June 30, 2018. six June 30, 2018 2017, not The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the same reported in the consolidated statement of cash flows: June 30, 2018 December 31, 2017 Cash and cash equivalents $ 6,833 $ 3,199 Restricted cash included in Other assets 475 474 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 7,308 $ 3,673 The restricted cash amount included in Other assets on the consolidated balance sheet represents amounts held as certificate of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the six June 30, 2018 2017, three During the six June 30, 2018 2017, 10% Three Months Ended Six Months Ended June 30, June 30, Major distribution or collaboration partner 201 8 201 7 201 8 201 7 Distributor A 21 % 23 % 21 % 23 % Distributor B 23 % 25 % 24 % 25 % Distributor C 24 % 18 % 25 % 20 % Collaborator D 10 % * 10 % * *Not 10% As of June 30, 2018 December 31, 2017, 10% Major distribution or collaboration partner June 30, 2018 December 31, 2017 Distributor A 26 % 25 % Distributor B 33 % 23 % Distributor C 24 % 22 % Collaborator D * 20 % *Not 10% The Company relies on two not third may not Fair Value of Financial Assets and Liabilities Financial instruments, including cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on U.S. GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under U.S. GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 Level 2 Level 3 Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. As of June 30, 2018 December 31, 2017, $11 $13 120 Inventory Inventory is comprised of ( 1 2 3 June 30, 2018 December 31, 2017, $138 $140 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with U.S. GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may no six June 30, 2018 June 30, 2017. not Comprehensive Income (Loss) Accounting Standards Codification (“ASC”) 220, Comprehensive Income Revenue Recognition Beginning January 1, 2018, 606, Revenue from Contracts with Customers The Company generates product revenue through product sales to its major distribution partners, a limited number of other distributors and via its webstore. Product supply is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a “sell-in” basis. Other revenue is primarily generated through commercial partner agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include more than one In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. ● Product supply ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply ● Incremental discounts and product supply prepayments considered material rights to the customer The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s or the Company’s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. Transaction Price The Company has both fixed and variable consideration. Under the Company’s license arrangements, non-refundable upfront fees are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Product supply selling prices are identified as variable consideration subject to the constraint on variable consideration for estimated discounts, rebates, chargebacks and product returns. Funding of research and development activities are considered variable payments until such costs are reimbursed, at which point they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. For product supply under the Company’s distribution arrangements, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company doesn’t have sufficient historical data to compute its own return rate, the return rate used to estimate the constraint on variable consideration for product returns is based on an average of peer and competitor company historical return rates. The Company updates the return rate assumption quarterly and applies it to the inventory balance that is held at the distributor and has not 30 one one At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for arrangements that contain multiple performance obligations, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. When a contract contains more than one Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method. The Company’s intellectual property in the form of distribution rights are determined to be distinct from the other performance obligations identified in the arrangements and considered “right to use” licenses which the customer can benefit from at a point in time. The Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license. Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may no may Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASU No. 2014 12, Compensation-Stock Compensation (Topic 718 12 Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liability For warrants that are newly issued or modified and there is a deemed possibility that the Company may Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three six June 30, 2018, $0.09 $0.22, $0.12 $0.26, three six June 30, 2017, no The following table sets forth the calculation of basic EPS and diluted EPS: Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Numerator Net loss $ (1,589 ) $ (1,738 ) $ (3,739 ) $ (5,749 ) Less gain on changes in fair value of warrant liability (490 ) - (704 ) - Net loss, diluted $ (2,079 ) $ (1,738 ) $ (4,443 ) $ (5,749 ) Denominator Weighted average shares outstanding, basic 17,089 15,308 16,750 15,296 Net loss per share, basic $ (0.09 ) $ (0.11 ) $ (0.22 ) $ (0.38 ) Weighted average shares outstanding, basic 17,089 15,308 16,750 15,296 Effect of dilutive warrants 203 - 235 - Weighted average shares outstanding, diluted 17,292 15,308 16,985 15,296 Net loss per share, diluted $ (0.12 ) $ (0.11 ) $ (0.26 ) $ (0.38 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of June 30, (in thousands) 2018 2017 Period end stock options to purchase common stock 3,189 2,828 Period end common stock warrants - 544 3,189 3,372 Recent Accounting Pronouncements In 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2015 2016, 606, 606, 606, December 15, 2017, one On January 1, 2018, 606 not January 1, 2018. not one January 1, 2018 606, not 605. 8 In November 2016, 2016 18, Statement of Cash Flows (Topic 230 one no one January 1, 2018 not In February 2016, 2016 02, Leases (Topic 842 ) Leases (Topic 840 ) 2016 02 first 2019. July 2017, 2017 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. 480 not December 15, 2018, 2017 11 In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting (Topic 718 718 718 December 15, 2018, no 606. 2018 07

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The Company measures the fair value of financial assets and liabilities based on authoritative guidance which defines fair value, establishes a framework consisting of three The Company’s warrant liability is classified within Level 3 The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2018: Fair Value Measurements Using (in thousands) Balance at June 30, 2018 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 102 $ 102 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 577 $ 577 $ — $ — Liabilities Warrant liability $ 785 $ — $ — $ 785 Total liabilities $ 785 $ — $ — $ 785 The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2017: Fair Value Measurements Using (in thousands) Balance at December 31, 2017 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 101 $ 101 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 575 $ 575 $ — $ — Liabilities Warrant liability $ 1,489 $ — $ — $ 1,489 Total liabilities $ 1,489 $ — $ — $ 1,489 As a result of the fair value adjustment of the warrant liability, the Company recorded a non-cash gain of $490 three June 30, 2018 10 (in thousands) Warrant liability Fair value of warrant liability at December 31, 2017 $ 1,489 Decrease in fair value at March 31, 2018 (214 ) Fair value of warrant liability at March 31, 2018 1,275 Decrease in fair value at June 30, 2018 (490 ) Fair value of warrant liability at June 30, 2018 $ 785

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following: (in thousands) June 30, 2018 December 31, 2017 Prepaid employees’ benefits $ 112 $ 112 Prepaid sales rebate 945 923 Prepaid rent - 123 Rent receivable 101 86 Prepaid insurance 57 27 Prepaid fleet leasing costs 75 61 Prepaid dues and subscriptions 93 117 Other 215 214 Total prepaid expenses and other current assets $ 1,598 $ 1,663

Note 5 - Inventory

Note 5 - Inventory	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following: (in thousands) June 30, 2018 December 31, 2017 Raw materials and supplies $ 270 $ 298 Finished goods 185 346 Less allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments (138 ) (140 ) Total inventory, net $ 317 $ 504

Note 6 - Property and Equipment

Note 6 - Property and Equipment	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following: (in thousands) June 30, 2018 December 31, 2017 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 157 157 Computer equipment and software 359 354 Production equipment 105 105 Leasehold improvements 76 74 Total property and equipment, at cost 721 714 Less: accumulated depreciation and amortization (370 ) (243 ) Total property and equipment, net $ 351 $ 471 Depreciation and amortization expense was $86 $18 three June 30, 2018 2017, $127 $36 six June 30, 2018 2017,

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. Accrued liabilities consisted of the following: (in thousands) June 30, 2018 December 31, 2017 Employee payroll and benefits $ 781 $ 761 Severance/retirement pay 171 347 Distributor fees and discounts - 185 Sales rebates - 106 Avenova contract liabilities (see Note 8) 1,487 - Deferred rent 85 69 Other 141 204 Total accrued liabilities $ 2,665 $ 1,672

Note 8 - Adoption of ASC Topic

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers"	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 8. 606, On January 1, 2018, 606 not January 1, 2018. not one January 1, 2018 606, not 605. Transactions under the Company’s major distribution agreements, which under prior guidance were recognized upon shipment from its distributors to the final customers, are now recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. As a result, the Company now records contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. The constraint on variable consideration for product returns is a new estimation resulting from the earlier recognition under the new guidance. Based on this change, the entire deferred revenue and deferred cost of goods sold balances related to its distribution agreements were allocated to either contract liabilities and other liabilities associated with invoicing in periods prior to adoption or included in the cumulative adjustment to retained earnings upon adoption. Milestone payments, which under the prior milestone recognition methodology were not may not may The following table shows the reconciliation of assets and liabilities disclosed in the Form 10 December 31, 2017, 606 January 1, 2018 ( As Reported Under Topic 605 Effect of Change As Adjusted Under Topic 606 Accounts receivable $ 3,629 $ 530 $ 4,159 Inventory $ 504 $ (25 ) $ 479 Accrued liabilities $ 1,672 $ 1,166 $ 2,838 Deferred revenue $ 2,841 $ (2,766 ) $ 75 Deferred revenue, non-current $ 534 $ (534 ) $ - Accumulated deficit $ (111,074 ) $ 2,639 $ (108,435 ) As a result of adopting Topic 606 six June 30, 2018, 605 As Reported Under Topic 606 Effect of Change As Revised Under Topic 605 Consolidated Balance Sheet: Accounts receivable $ 2,024 $ (315 ) $ 1,709 Inventory $ 317 $ 19 $ 336 Accrued liabilities $ 2,665 $ (1,267 ) $ 1,398 Deferred revenue $ 62 $ 2,829 $ 2,891 Deferred revenue, non-current $ - $ 581 $ 581 Accumulated deficit $ (112,175 ) $ (2,439 ) $ (114,614 ) Total net sales $ 5,741 $ 205 $ 5,946 Cost of product sales $ 730 $ 6 $ 736 Loss from operations $ (4,451 ) $ 199 $ (4,252 ) Net loss $ (3,739 ) $ 199 $ (3,540 ) Basic net loss per share $ (0.22 ) $ 0.01 $ (0.21 ) Diluted net loss per share $ (0.26 ) $ 0.01 $ (0.25 ) Consolidated Statement of Cash Flows: Net loss $ (3,739 ) $ 199 $ (3,540 ) Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable $ 2,134 $ (215 ) $ 1,919 Inventory $ 160 $ 6 $ 166 Accounts payable and accrued liabilities $ (327 ) $ (132 ) $ (459 ) Deferred revenue $ (13 ) $ 141 $ 128 At June 30, 2018, $62,000 2018. For additional detail on the Company’s accounting policy regarding revenue recognition, refer to Note 2 The following table presents changes in the Company’s contract assets and liabilities for the six June 30, 2018: Balance at Beginning of the Period Additions Deductions Balance at the end of the Period (in thousands) Contract Liabilities: Deferred Revenue $ 75 $ - $ (13 ) $ 62 Contract Liabilities: Accrued Liabilities $ 1,458 $ 6,516 $ (6,396 ) $ 1,578 Total $ 1,533 $ 6,516 $ (6,409 ) $ 1,640 During the six June 30, 2018, Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,426 New activities in the period: Performance obligations satisfied $ 4,315 Total revenue $ 5,741 License Collaboration and Distribution Agreements In January 2012, $312,500. $312,500 January 2013 first December 31, 2014, $625,000 In September 2012, two 1 2 one one Pursuant to the terms of the Distribution Agreement, China Pioneer has the right to distribute NeutroPhase, upon a marketing approval from a Regulatory Authority, in certain territories in Asia (other than China). Upon execution of the Distribution Agreement, the Company received an upfront payment, which was recorded as deferred revenue. China Pioneer is also obligated to make certain additional payments to the Company upon receipt of the marketing approval. The Distribution Agreement further provides that China Pioneer is entitled to a cumulative purchase discount not $500,000 Pursuant to the Purchase Agreement, the Company also received $2.5 one one two 1 800,000 September 2012; 2 1,200,000 October 2012, $1.25 $3.5 $2.5 $1 $600,000 In December 2013, 11 On February 7, 2012, $750,000. In April 2013, 422 $250,000. On June 1, 2013, $200,000. Revenue has been recognized under these agreements as follows: Three Months Ended Six Months Ended June 30, June 30, (in thousands) 2018 2017 2018 2017 Amortization of upfront technology access fee $ - $ 28 $ 13 $ 35 Product revenue 121 289 121 362 Total revenue recognized $ 121 $ 317 $ 134 $ 397 The Company had a deferred revenue balance of $2.0 December 31, 2017, 606, $1.96 June 30, 2018, $62 Avenova Distribution Agreements In November 2014, January 2015, April 2015, During the three June 30, 2018 2017, $2.3 $3.0 $4.9 $5.8 six June 30, 2018 2017, The Company had a deferred revenue balance of $1.3 December 31, 2017 not 606, $1.3 $0.6 $0.7 606, At June 30, 2018, $1.6 7

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 9. Operating Leases Facility Lease On August 24, 2016, 7,799 eleventh 1150 2000 94608 February 28, 2022, one five 5 no twelve 12 no nine 9 The Company still has a lease commitment for the laboratory facilities and office space at Suite 550, 5980 October 31, 2020. July 11, 2016, 16,465 September 8, 2016. October 21, 2020, October 31, 2020), Rent expense, net for the above two $96 $97 three June 30, 2018 2017, $193 $196 six June 30, 2018 2017, The Company’s monthly rent payments fluctuate under the various leases and sublease agreements. In accordance with U.S. GAAP, the Company recognizes rent expense on a straight-line basis. The Company records deferred rent and sublease future minimum payments receivable for the difference between the amounts paid and recorded as expense. Vehicle Fleet Leases During the six June 30, 2018, 54 36 June 30, 2018, 54 $14 $15 $3 36 Lease expense, net, for the vehicle fleet was approximately $31 $39 three June 30, 2018 2017, $62 $56 six June 30, 2018 2017, Directors and Officers Indemnification As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not June 30, 2018. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not June 30, 2018. Legal Matters From time to time, the Company may no June 30, 2018,

Note 10 - Warrant Liability

Note 10 - Warrant Liability	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 10. In July 2011, 139,520 $33.25 January 1, 2012 July 5, 2016. 480, Distinguishing Liabilities from Equity 480 January 5, 2012, $66.50 ten not fifteen one third In October 2015, March 3, 2015 ( “2015 twenty two March 3, 2016). October 2015 15 five 2015 “March 2015 June 29, 2011 ( “July 2011 March 2015 July 2011 $5.00 July 2011 March 6, 2020. July 2011 March 2015 $5.00 $5.00, In October 2015, 492,000 442,802 “October 2015 $5.00 “October 2015 60 October 2015 $5.00 $2.1 In February 2016, July 2011, March 2015 October 2015 $1.81 The key assumptions used to value the July 2011 June 30, 2018 December 31, 2017 As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 66.00 % 91.00 % Expected term (in years) 1.68 2.18 Risk-free interest rate 2.46 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.42 $ 2.72 In March 2015, $15.00 $16.25 not March 2015 July 2011 October 2015, March 2015 March 2015 October 27, 2015 $1.8 October 27, 2015 October 27, 2015. The key assumptions used to value the Short-Term Warrants as of June 30, 2018 December 31, 2017 As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 66.00 % 91.00 % Expected term (in years) 1.68 2.18 Risk-free interest rate 2.46 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.13 $ 2.42 The key assumptions used to value the Long-Term Warrants as of June 30, 2018 December 31, 2017 As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 66.00 % 91.00 % Expected term (in years) 1.68 2.18 Risk-free interest rate 2.46 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.42 $ 2.72 As noted above, the Company issued warrants in connection with the October 2015 October 2015 480, 480 October 27, 2015 $1.3 The key assumptions used to value the October 2015 June 30, 2018 December 31, 2017 As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 73.00 % 90.00 % Expected term (in years) 2.33 2.83 Risk-free interest rate 2.56 % 1.96 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.58 $ 2.86 During the third 2016, 3,613,284 3,613,284 July 2011, March 2015 October 2015, $6.9 $1.6 $1.6 During the fourth 2016, 363,523 363,523 October 2015, November 2015 December 2015 $0.9 $0.5 $0.5 During the second 2017, 21,000 21,000 March 2015 $38 $58 $58 The details of the outstanding warrant liability as of June 30, 2018, Shares and dollars in thousands Shares Warrant Liability July 2011 Warrants 49 $ 70 Long-Term Warrants 96 136 Short-Term Warrants 115 130 October 2015 Warrants 284 449 544 $ 785

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 11. Amendments to Articles of Incorporation—Reverse Stock Split Effective December 18, 2015, 1 25 December 11, 2015. After approval by the Company’s stockholders, the Company decreased the number of authorized shares from 240 50 June 4, 2018. Preferred Stock Under the Company’s amended articles of incorporation, the Company is authorized to issue up to 5,000,000 may June 30, 2018 December 31, 2017, no Common Stock In February 2016, three 1,518,567 $2.8 first 696,590 $1.81, five 5% February 16, 2016, second 696,590 $1.91, February 16, 2016 no third 125,387 $1.91, February 16, 2016 no not may not China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six 6% $155 On April 4, 2016, 6,173,299 $0.01 “April 2016 3,086,651 $11.8 4 $1.91, $4.00 five two first May 5, 2016, $7.8 second August 1, 2016, $4.0 4,079,058 April 2016 2,039,530 2,094,241 April 2016 1,047,121 China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six 6% $618 Also on April 4, 2016, may April 2016 April 2016 June 9, 2016 June 20, 2016 ( 333 211943 During the third 2016, $6.6 3,613,284 3,613,284 May 2016 August 2016. six 6% $338 During the fourth 2016, $0.9 363,523 363,523 six 6% $32 During the first 2018, 1,700,000 $0.01 $5,984,000 February 8, 2018. six 6% $359,040. $34 Stock Warrants In February 2016, July 2011, March 2015 October 2015 $1.81 In May 2016, 2,039,530 In August 2016, 1,047,121 Effective September 29, 2016, May 18, 2015, $19.50 $3.15 sixteen 16% September 27, 2016. $270 The details of all outstanding warrants as of June 30, 2018, (in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2017 544 $ 1.81 Warrants granted — — Warrants exercised — — Warrants expired — — Warrants outstanding June 30, 2018 544 $ 1.81

Note 12 - Equity-based Compensa

Note 12 - Equity-based Compensation	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 12. Equity Compensation Plans In October 2007, 2007 “2007 2007 40,000 2007 For the years from 2009 2012, 2007 40,000 4% 40,000, 37,427, 37,207 2007 January 2012, 2011 2010, 2013, 40,000 2007 4% 32,646 59,157 2007 January 2014 2013, March 30, 2015, 82,461 2007 January 2016, 139,449 2007 2007 May 26, 2016, 2007 1,124,826 January 2017, 610,774 2007 2007 2007 2,318,486 March 15, 2017 ( 2007 Upon expiration of the 2007 2007 March 15, 2017 2007 may not 100% 10% not 110% 2007 no ten four In March 2017, 2017 “2017 June 2, 2017, 2017 not 2007 2017 2,318,486 first January 1, 2018 January 1, 2027 four 4 2017 January 2018, 615,392 2017 2017 June 30, 2018, 1,383,470 2017 Under the terms of the 2017 may not 100% 10% not 110% not ten not five ten four 2007 2017 Stock Option Summary The following table summarizes information about the Company’s stock options outstanding at June 30, 2018, six (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2017 2,960 $ 5.16 8.6 $ 2,586 Options granted 814 $ 2.21 Restricted stock units granted 12 $ — Options exercised (4 ) $ 2.35 Restricted stock units vested - $ — Options forfeited/cancelled (593 ) $ 5.18 Restricted stock units cancelled - $ — Outstanding at June 30, 2018 3,189 $ 4.39 8.6 $ 412 Vested and expected to vest at June 30, 2018 2,829 $ 4.62 8.6 $ 362 Vested at June 30, 2018 1,524 $ 6.42 7.7 $ — Exercisable at June 30, 2018 1,524 $ 6.42 7.7 $ — For options that have a quoted market price in excess of the exercise price (“in-the-money options”), the aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as reported on the NYSE American as of June 30, 2018. no three June 30, 2018. 4 six June 30, 2018 $11 $1 six June 30, 2018. no three six June 30, 2017. no three six June 30, 2017. As of June 30, 2018, $2.3 3.17 Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes-Merton option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2 During the six June 30, 2018 2017, 809 1,292 The weighted-average assumptions used in determining the value of options are as follows: Six Months Ended June 30, Assumption 2018 2017 Expected price volatility 88.86 % 87.72 % Expected term (in years) 5.97 6.90 Risk-free interest rate 2.71 % 2.11 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.64 $ 2.25 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. Additionally, during the six June 30, 2018, 12 six June 30, 2017, not For the three June 30, 2018 2017, $148 $442 six June 30, 2018 2017, $327 $1,600 In March 2018, March 21, 2018. three three $26 Stock-Based Awards to Non-Employees During the six June 30, 2018 2017, 5 85 The stock options are recorded at their fair value on the measurement date and recognized over the respective service or vesting period. The fair value of the stock options granted was calculated using the Black-Scholes-Merton option pricing model based upon the following assumptions: Six Months Ended June 30, Assumption 2018 2017 Expected price volatility 84.83 % 87.42 % Expected term (in years) 10.0 10.00 Risk-free interest rate 2.81 % 2.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.86 $ 2.38 The Company granted 31 six June 30, 2017, For the three June 30, 2018 2017, $6 $53 six June 30, 2018 2017, $13 $89 In November 2015, December 2016, 2016. December 31, 2015, December 2016. January 2017, Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the option and stock awards discussed above is as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2018 2017 2018 2017 Research and development $ 12 $ 28 $ 19 $ 49 Sales and Marketing 45 57 79 94 General and administrative 97 411 242 1,546 Total stock-based compensation expense $ 154 $ 496 $ 340 $ 1,689 Since the Company has operating losses and net operating loss carryforwards, there are no

Note 13 - Employee Benefit Plan

Note 13 - Employee Benefit Plan	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 13. The Company has a 401 not no six June 30, 2018.

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 14. Related Party Financing See Note 11, February 2016 April 2016 two Related Party Revenue The Company recognized related party revenues from product sales and license and collaboration fees of zero $9 three June 30, 2018 2017, $13 $15 six June 30, 2018 2017, no June 30, 2018 December 31, 2017. 8, 606, Revenue from contracts with customers , Related Party Expenses The Company recognized no three June 30, 2018 2017, $359 zero six June 30, 2018 2017, 11,

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars.
Reclassification, Policy [Policy Text Block]	Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. Prior period amounts in the accompanying consolidated statements of operations and comprehensive loss have also been reclassified to conform to current period presentation. The reclassifications did not Additionally, prior period amounts in the accompanying consolidated statements of cash flow have also been reclassified to conform to current period presentation. The reclassifications did not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three June 30, 2018, December 31, 2017, two Beginning fiscal 2018, No. 2016 18, Statement of Cash Flows (Topic 230 $474 December 31, 2017, $475 June 30, 2018. six June 30, 2018 2017, not The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the same reported in the consolidated statement of cash flows: June 30, 2018 December 31, 2017 Cash and cash equivalents $ 6,833 $ 3,199 Restricted cash included in Other assets 475 474 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 7,308 $ 3,673 The restricted cash amount included in Other assets on the consolidated balance sheet represents amounts held as certificate of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the six June 30, 2018 2017, three During the six June 30, 2018 2017, 10% Three Months Ended Six Months Ended June 30, June 30, Major distribution or collaboration partner 201 8 201 7 201 8 201 7 Distributor A 21 % 23 % 21 % 23 % Distributor B 23 % 25 % 24 % 25 % Distributor C 24 % 18 % 25 % 20 % Collaborator D 10 % * 10 % * *Not 10% As of June 30, 2018 December 31, 2017, 10% Major distribution or collaboration partner June 30, 2018 December 31, 2017 Distributor A 26 % 25 % Distributor B 33 % 23 % Distributor C 24 % 22 % Collaborator D * 20 % *Not 10% The Company relies on two not third may not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities Financial instruments, including cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on U.S. GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under U.S. GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 Level 2 Level 3
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. As of June 30, 2018 December 31, 2017, $11 $13 120
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 June 30, 2018 December 31, 2017, $138 $140 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with U.S. GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may no six June 30, 2018 June 30, 2017. not
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) Accounting Standards Codification (“ASC”) 220, Comprehensive Income
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Beginning January 1, 2018, 606, Revenue from Contracts with Customers The Company generates product revenue through product sales to its major distribution partners, a limited number of other distributors and via its webstore. Product supply is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a “sell-in” basis. Other revenue is primarily generated through commercial partner agreements with strategic partners for the development and commercialization of the Company’s product candidates. The terms of the agreements typically include more than one In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. ● Product supply ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply ● Incremental discounts and product supply prepayments considered material rights to the customer The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s or the Company’s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. Transaction Price The Company has both fixed and variable consideration. Under the Company’s license arrangements, non-refundable upfront fees are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Product supply selling prices are identified as variable consideration subject to the constraint on variable consideration for estimated discounts, rebates, chargebacks and product returns. Funding of research and development activities are considered variable payments until such costs are reimbursed, at which point they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. For product supply under the Company’s distribution arrangements, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company doesn’t have sufficient historical data to compute its own return rate, the return rate used to estimate the constraint on variable consideration for product returns is based on an average of peer and competitor company historical return rates. The Company updates the return rate assumption quarterly and applies it to the inventory balance that is held at the distributor and has not 30 one one At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for arrangements that contain multiple performance obligations, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. When a contract contains more than one Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method. The Company’s intellectual property in the form of distribution rights are determined to be distinct from the other performance obligations identified in the arrangements and considered “right to use” licenses which the customer can benefit from at a point in time. The Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license.
Cost of Sales, Policy [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may no may
Legal Costs, Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASU No. 2014 12, Compensation-Stock Compensation (Topic 718 12
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liability For warrants that are newly issued or modified and there is a deemed possibility that the Company may
Earnings Per Share, Policy [Policy Text Block]	Net (Loss) per Share The Company computes net (loss) per share by presenting both basic and diluted (loss) per share (“EPS”). Basic EPS is computed by dividing net (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods since their effect would be anti-dilutive. During the three six June 30, 2018, $0.09 $0.22, $0.12 $0.26, three six June 30, 2017, no The following table sets forth the calculation of basic EPS and diluted EPS: Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Numerator Net loss $ (1,589 ) $ (1,738 ) $ (3,739 ) $ (5,749 ) Less gain on changes in fair value of warrant liability (490 ) - (704 ) - Net loss, diluted $ (2,079 ) $ (1,738 ) $ (4,443 ) $ (5,749 ) Denominator Weighted average shares outstanding, basic 17,089 15,308 16,750 15,296 Net loss per share, basic $ (0.09 ) $ (0.11 ) $ (0.22 ) $ (0.38 ) Weighted average shares outstanding, basic 17,089 15,308 16,750 15,296 Effect of dilutive warrants 203 - 235 - Weighted average shares outstanding, diluted 17,292 15,308 16,985 15,296 Net loss per share, diluted $ (0.12 ) $ (0.11 ) $ (0.26 ) $ (0.38 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of June 30, (in thousands) 2018 2017 Period end stock options to purchase common stock 3,189 2,828 Period end common stock warrants - 544 3,189 3,372
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2015 2016, 606, 606, 606, December 15, 2017, one On January 1, 2018, 606 not January 1, 2018. not one January 1, 2018 606, not 605. 8 In November 2016, 2016 18, Statement of Cash Flows (Topic 230 one no one January 1, 2018 not In February 2016, 2016 02, Leases (Topic 842 ) Leases (Topic 840 ) 2016 02 first 2019. July 2017, 2017 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. 480 not December 15, 2018, 2017 11 In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting (Topic 718 718 718 December 15, 2018, no 606. 2018 07

Note 2 - Summary of Significa21

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	June 30, 2018 December 31, 2017 Cash and cash equivalents $ 6,833 $ 3,199 Restricted cash included in Other assets 475 474 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 7,308 $ 3,673
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, Major distribution or collaboration partner 201 8 201 7 201 8 201 7 Distributor A 21 % 23 % 21 % 23 % Distributor B 23 % 25 % 24 % 25 % Distributor C 24 % 18 % 25 % 20 % Collaborator D 10 % * 10 % * Major distribution or collaboration partner June 30, 2018 December 31, 2017 Distributor A 26 % 25 % Distributor B 33 % 23 % Distributor C 24 % 22 % Collaborator D * 20 %
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Numerator Net loss $ (1,589 ) $ (1,738 ) $ (3,739 ) $ (5,749 ) Less gain on changes in fair value of warrant liability (490 ) - (704 ) - Net loss, diluted $ (2,079 ) $ (1,738 ) $ (4,443 ) $ (5,749 ) Denominator Weighted average shares outstanding, basic 17,089 15,308 16,750 15,296 Net loss per share, basic $ (0.09 ) $ (0.11 ) $ (0.22 ) $ (0.38 ) Weighted average shares outstanding, basic 17,089 15,308 16,750 15,296 Effect of dilutive warrants 203 - 235 - Weighted average shares outstanding, diluted 17,292 15,308 16,985 15,296 Net loss per share, diluted $ (0.12 ) $ (0.11 ) $ (0.26 ) $ (0.38 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of June 30, (in thousands) 2018 2017 Period end stock options to purchase common stock 3,189 2,828 Period end common stock warrants - 544 3,189 3,372

Note 3 - Fair Value Measureme22

Note 3 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using (in thousands) Balance at June 30, 2018 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 102 $ 102 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 577 $ 577 $ — $ — Liabilities Warrant liability $ 785 $ — $ — $ 785 Total liabilities $ 785 $ — $ — $ 785 Fair Value Measurements Using (in thousands) Balance at December 31, 2017 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash equivalents $ 101 $ 101 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 575 $ 575 $ — $ — Liabilities Warrant liability $ 1,489 $ — $ — $ 1,489 Total liabilities $ 1,489 $ — $ — $ 1,489
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands) Warrant liability Fair value of warrant liability at December 31, 2017 $ 1,489 Decrease in fair value at March 31, 2018 (214 ) Fair value of warrant liability at March 31, 2018 1,275 Decrease in fair value at June 30, 2018 (490 ) Fair value of warrant liability at June 30, 2018 $ 785

Note 4 - Prepaid Expenses and23

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	(in thousands) June 30, 2018 December 31, 2017 Prepaid employees’ benefits $ 112 $ 112 Prepaid sales rebate 945 923 Prepaid rent - 123 Rent receivable 101 86 Prepaid insurance 57 27 Prepaid fleet leasing costs 75 61 Prepaid dues and subscriptions 93 117 Other 215 214 Total prepaid expenses and other current assets $ 1,598 $ 1,663

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(in thousands) June 30, 2018 December 31, 2017 Raw materials and supplies $ 270 $ 298 Finished goods 185 346 Less allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments (138 ) (140 ) Total inventory, net $ 317 $ 504

Note 6 - Property and Equipme25

Note 6 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	(in thousands) June 30, 2018 December 31, 2017 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 157 157 Computer equipment and software 359 354 Production equipment 105 105 Leasehold improvements 76 74 Total property and equipment, at cost 721 714 Less: accumulated depreciation and amortization (370 ) (243 ) Total property and equipment, net $ 351 $ 471

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(in thousands) June 30, 2018 December 31, 2017 Employee payroll and benefits $ 781 $ 761 Severance/retirement pay 171 347 Distributor fees and discounts - 185 Sales rebates - 106 Avenova contract liabilities (see Note 8) 1,487 - Deferred rent 85 69 Other 141 204 Total accrued liabilities $ 2,665 $ 1,672

Note 8 - Adoption of ASC Topi27

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers" (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Revenue, Initial Application Period Cumulative Effect Transition [Table Text Block]	As Reported Under Topic 605 Effect of Change As Adjusted Under Topic 606 Accounts receivable $ 3,629 $ 530 $ 4,159 Inventory $ 504 $ (25 ) $ 479 Accrued liabilities $ 1,672 $ 1,166 $ 2,838 Deferred revenue $ 2,841 $ (2,766 ) $ 75 Deferred revenue, non-current $ 534 $ (534 ) $ - Accumulated deficit $ (111,074 ) $ 2,639 $ (108,435 ) As Reported Under Topic 606 Effect of Change As Revised Under Topic 605 Consolidated Balance Sheet: Accounts receivable $ 2,024 $ (315 ) $ 1,709 Inventory $ 317 $ 19 $ 336 Accrued liabilities $ 2,665 $ (1,267 ) $ 1,398 Deferred revenue $ 62 $ 2,829 $ 2,891 Deferred revenue, non-current $ - $ 581 $ 581 Accumulated deficit $ (112,175 ) $ (2,439 ) $ (114,614 ) Total net sales $ 5,741 $ 205 $ 5,946 Cost of product sales $ 730 $ 6 $ 736 Loss from operations $ (4,451 ) $ 199 $ (4,252 ) Net loss $ (3,739 ) $ 199 $ (3,540 ) Basic net loss per share $ (0.22 ) $ 0.01 $ (0.21 ) Diluted net loss per share $ (0.26 ) $ 0.01 $ (0.25 ) Consolidated Statement of Cash Flows: Net loss $ (3,739 ) $ 199 $ (3,540 ) Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable $ 2,134 $ (215 ) $ 1,919 Inventory $ 160 $ 6 $ 166 Accounts payable and accrued liabilities $ (327 ) $ (132 ) $ (459 ) Deferred revenue $ (13 ) $ 141 $ 128
Contract with Customer, Asset and Liability [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period (in thousands) Contract Liabilities: Deferred Revenue $ 75 $ - $ (13 ) $ 62 Contract Liabilities: Accrued Liabilities $ 1,458 $ 6,516 $ (6,396 ) $ 1,578 Total $ 1,533 $ 6,516 $ (6,409 ) $ 1,640
Disaggregation of Revenue [Table Text Block]	Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,426 New activities in the period: Performance obligations satisfied $ 4,315 Total revenue $ 5,741
Schedule of Revenue Recognized [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, (in thousands) 2018 2017 2018 2017 Amortization of upfront technology access fee $ - $ 28 $ 13 $ 35 Product revenue 121 289 121 362 Total revenue recognized $ 121 $ 317 $ 134 $ 397

Note 10 - Warrant Liability (Ta

Note 10 - Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 66.00 % 91.00 % Expected term (in years) 1.68 2.18 Risk-free interest rate 2.46 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.42 $ 2.72 As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 66.00 % 91.00 % Expected term (in years) 1.68 2.18 Risk-free interest rate 2.46 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.13 $ 2.42 As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 66.00 % 91.00 % Expected term (in years) 1.68 2.18 Risk-free interest rate 2.46 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.42 $ 2.72 As of Assumption June 30, 2018 December 31, 2017 Expected price volatility 73.00 % 90.00 % Expected term (in years) 2.33 2.83 Risk-free interest rate 2.56 % 1.96 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.58 $ 2.86
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2017 544 $ 1.81 Warrants granted — — Warrants exercised — — Warrants expired — — Warrants outstanding June 30, 2018 544 $ 1.81
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Shares and dollars in thousands Shares Warrant Liability July 2011 Warrants 49 $ 70 Long-Term Warrants 96 136 Short-Term Warrants 115 130 October 2015 Warrants 284 449 544 $ 785

Note 11 - Stockholders' Equit29

Note 11 - Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	(in thousands, except for exercise price) Warrants Weighted- Average Exercise Price Warrants outstanding December 31, 2017 544 $ 1.81 Warrants granted — — Warrants exercised — — Warrants expired — — Warrants outstanding June 30, 2018 544 $ 1.81

Note 12 - Equity-based Compen30

Note 12 - Equity-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2017 2,960 $ 5.16 8.6 $ 2,586 Options granted 814 $ 2.21 Restricted stock units granted 12 $ — Options exercised (4 ) $ 2.35 Restricted stock units vested - $ — Options forfeited/cancelled (593 ) $ 5.18 Restricted stock units cancelled - $ — Outstanding at June 30, 2018 3,189 $ 4.39 8.6 $ 412 Vested and expected to vest at June 30, 2018 2,829 $ 4.62 8.6 $ 362 Vested at June 30, 2018 1,524 $ 6.42 7.7 $ — Exercisable at June 30, 2018 1,524 $ 6.42 7.7 $ —
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2018 2017 2018 2017 Research and development $ 12 $ 28 $ 19 $ 49 Sales and Marketing 45 57 79 94 General and administrative 97 411 242 1,546 Total stock-based compensation expense $ 154 $ 496 $ 340 $ 1,689
Nonemployees [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, Assumption 2018 2017 Expected price volatility 84.83 % 87.42 % Expected term (in years) 10.0 10.00 Risk-free interest rate 2.81 % 2.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.86 $ 2.38
Employees and Directors [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, Assumption 2018 2017 Expected price volatility 88.86 % 87.72 % Expected term (in years) 5.97 6.90 Risk-free interest rate 2.71 % 2.11 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.64 $ 2.25

Note 1 - Organization (Details

Note 1 - Organization (Details Textual)	Dec. 18, 2015	Dec. 11, 2015
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25	25

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance	$ 7,308	$ 6,196	$ 7,308	$ 6,196	$ 3,673	$ 9,986
Inventory Valuation Reserves, Ending Balance	$ 138		138		140
Impairment of Long-Lived Assets Held-for-use			$ 0	$ 0
Earnings Per Share, Basic, Total	$ (0.09)	$ (0.11)	$ (0.22)	$ (0.38)
Earnings Per Share, Diluted, Total	$ (0.12)	$ (0.11)	$ (0.26)	$ (0.38)
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years
Computer Equipment and Software [Member]
Property, Plant and Equipment, Useful Life			3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life			7 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years
SEC Schedule, 12-09, Allowance, Credit Loss [Member]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	$ 11		$ 11		13
Accounting Standards Update 2016-18 [Member]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance	$ 475		$ 475		$ 474

Note 2 - Summary of Significa33

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 6,833	$ 3,199
Restricted cash included in Other assets	475	474
Total cash, cash equivalents, and restricted cash in the statement of cash flows	$ 7,308	$ 3,673	$ 6,196	$ 9,986

Note 2 - Summary of Significa34

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018		Jun. 30, 2017
Sales Revenue, Net [Member] | Distributor A [Member]
Distributor A	21.00%	23.00%	21.00%		23.00%
Sales Revenue, Net [Member] | Distributor B [Member]
Distributor A	23.00%	25.00%	24.00%		25.00%
Sales Revenue, Net [Member] | Distributor C [Member]
Distributor A	24.00%	18.00%	25.00%		20.00%
Sales Revenue, Net [Member] | Distributor D [Member]
Distributor A	10.00%		10.00%			[1]
Accounts Receivable [Member] | Distributor A [Member]
Distributor A			26.00%		25.00%
Accounts Receivable [Member] | Distributor B [Member]
Distributor A			33.00%		23.00%
Accounts Receivable [Member] | Distributor C [Member]
Distributor A			24.00%		22.00%
Accounts Receivable [Member] | Collaborator D [Member]
Distributor A				[1]	20.00%
[1]	Not greater than 10%

Note 2 - Summary of Significa35

Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss	$ (1,589)	$ (1,738)	$ (3,739)	$ (5,749)
Less gain on changes in fair value of warrant liability	(490)		(704)
Net loss, diluted	$ (2,079)	$ (1,738)	$ (4,443)	$ (5,749)
Weighted average shares outstanding, basic (in shares)	17,089	15,308	16,750	15,296
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.09)	$ (0.11)	$ (0.22)	$ (0.38)
Effect of dilutive warrants (in shares)	203		235
Weighted average shares outstanding, diluted (in shares)	17,292	15,308	16,985	15,296
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.12)	$ (0.11)	$ (0.26)	$ (0.38)

Note 2 - Summary of Significa36

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Anti-dilutive stock options and stock warrants (in shares)	3,189	3,372
Employee Stock Option [Member]
Anti-dilutive stock options and stock warrants (in shares)	3,189	2,828
Warrant [Member]
Anti-dilutive stock options and stock warrants (in shares)		544

Note 3 - Fair Value Measureme37

Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Fair Value Adjustment of Warrants	$ (490)	$ (15)	$ (704)	$ 220

Note 3 - Fair Value Measureme38

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Cash equivalents	$ 102	$ 101
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	150
Total assets	577	575
Warrant liability	785	1,489
Total liabilities	785	1,489
Fair Value, Inputs, Level 1 [Member]
Cash equivalents	102	101
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	150
Total assets	577	575
Warrant liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability	785	1,489
Total liabilities	$ 785	$ 1,489

Note 3 - Fair Value Measureme39

Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - Warrant Liability [Member] - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Fair value of warrant liability	$ 1,275	$ 1,489
Decrease in fair value at March 31, 2018	(490)	(214)
Fair value of warrant liability	$ 785	$ 1,275

Note 4 - Prepaid Expenses and40

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Prepaid employees’ benefits	$ 112	$ 112
Prepaid sales rebate	945	923
Prepaid rent		123
Rent receivable	101	86
Prepaid insurance	57	27
Prepaid fleet leasing costs	75	61
Prepaid dues and subscriptions	93	117
Other	215	214
Total prepaid expenses and other current assets	$ 1,598	$ 1,663

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Raw materials and supplies	$ 270		$ 298
Finished goods	185		346
Less allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	(138)		(140)
Total inventory, net	$ 317	$ 479	$ 504

Note 6 - Property and Equipme42

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Depreciation, Depletion and Amortization, Total	$ 86	$ 18	$ 127	$ 36

Note 6 - Property and Equipme43

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property and equipment, at cost	$ 721	$ 714
Less: accumulated depreciation and amortization	(370)	(243)
Total property and equipment, net	351	471
Equipment [Member]
Property and equipment, at cost	24	24
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	359	354
Production Equipment [Member]
Property and equipment, at cost	105	105
Leasehold Improvements [Member]
Property and equipment, at cost	$ 76	$ 74

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Employee payroll and benefits	$ 781		$ 761
Severance/retirement pay	171		347
Distributor fees and discounts			185
Sales rebates			106
Avenova contract liabilities (see Note 8)	1,487		1,458
Deferred rent	85		69
Other	141		204
Total accrued liabilities	$ 2,665	$ 2,838	$ 1,672

Note 8 - Adoption of ASC Topi45

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers" 1 (Details Textual) - USD ($)

Jun. 01, 2013

Feb. 07, 2012

Apr. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Sep. 30, 2012

Jan. 31, 2012

Oct. 31, 2012

Jun. 30, 2018

Jun. 30, 2017

Dec. 31, 2012

Jun. 30, 2018

Jun. 30, 2017

Dec. 31, 2014

Jan. 01, 2018

Dec. 31, 2017

Mar. 31, 2017

Contract with Customer, Liability, Revenue Recognized

$ 121,000

$ 317,000

$ 134,000

$ 397,000

Contract with Customer, Liability, Product Distribution, Current

1,487,000

1,487,000

$ 1,458,000

Restricted Stock Purchase [Member]

Excess Fair Value Over Proceeds Received From Purchase

$ 1,000,000

Tranche One [Member]

Purchase Agreement Units

800,000

Tranche Two [Member]

Purchase Agreement Units

1,200,000

Purchase Agreement Unit Price Per Share

$ 1.25

Purchase Unit Agreement Total Units Fair Value

$ 3,500,000

Reallocated from Deferred Revenue [Member]

Stockholders' Equity, Period Increase (Decrease), Total

$ 600,000

Restricted Stock Units (RSUs) [Member]

Proceeds from Issuance or Sale of Equity, Total

$ 2,500,000

Technology Service [Member]

Deferred Revenue

2,000,000

Contract with Customer, Liability, Revenue Recognized

28,000

13,000

35,000

Technology Service [Member] | Deferred Revenue Decreased and Recorded as Part of The Cumulative Adjustment to Accumulated Deficit Related to ASU 2014-09 [Member]

Contract with Customer, Liability, Total

$ 1,960,000

Avenova Product [Member] | Deferred Revenue Decreased and Recorded as Part of The Cumulative Adjustment to Accumulated Deficit Related to ASU 2014-09 [Member]

Contract with Customer, Liability, Total

1,300,000

Avenova Product [Member] | Service Fees/Chargebacks, Prompt Payment Discounts, Rebates and Returns Reclassified to Contract Liability That is Related to ASU 2014-09 [Member]

Contract with Customer, Liability, Total

600,000

Avenova Product [Member] | Cumulative Adjustment To The Accumulated Deficit, Including The Net Effect of Deferred Cost of Goods Sold, Related to ASU 2014-09 [Member]

Contract with Customer, Liability, Total

$ 700,000

China Pioneer [Member] | Neutrophase [Member]

Proceeds from Collaborators

$ 312,500

$ 312,500

$ 625,000

Maximum Possible Sales Discounts

500,000

Integrated Healing Technologies, LLC [Member] | Neutrophase [Member]

Proceeds from Collaborators

$ 750,000

Virbac [Member] | Auriclosene (NVC-422) [Member]

Proceeds from Collaborators

$ 250,000

Principal Business Enterprise, Inc. [Member] | Neutrophase [Member]

Proceeds from Collaborators

$ 200,000

China Pioneer and Principal Business Enterprise Inc. [Member] | Samples and Future Products [Member]

Revenue, Remaining Performance Obligation, Amount

$ 62,000

McKesson Corporation [Member] | Avenova Product [Member]

Deferred Revenue

$ 1,300,000

Contract with Customer, Liability, Revenue Recognized

2,300,000

$ 3,000,000

4,900,000

$ 5,800,000

Contract with Customer, Liability, Product Distribution, Current

$ 1,600,000

$ 1,600,000

Note 8 - Adoption of ASC Topi46

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers" 2 (Details Textual)	Jun. 30, 2018USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-07-01
Revenue, Remaining Performance Obligation, Amount	$ 62,000

Note 8 - Adoption of ASC Topi47

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers" - Reconciliation of Assets and Liabilities (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Accounts receivable	$ 2,024			$ 2,024		$ 4,159	$ 3,629
Inventory	317			317		479	504
Accrued liabilities	2,665			2,665		2,838	1,672
Deferred revenue	62			62		75	75
Deferred revenue, non-current							534
Accumulated deficit	(112,175)			(112,175)		(108,435)	$ (111,074)
Total net sales	2,794		$ 4,122	5,741	$ 7,823
Cost of product sales	479		698	730	1,286
Loss from operations	(2,083)		(1,757)	(4,451)	(5,534)
Net loss	$ (1,589)		$ (1,738)	$ (3,739)	$ (5,749)
Earnings Per Share, Basic, Total	$ (0.09)		$ (0.11)	$ (0.22)	$ (0.38)
Earnings Per Share, Diluted, Total	$ (0.12)		$ (0.11)	$ (0.26)	$ (0.38)
Accounts receivable				$ 2,134	$ (1,480)
Inventory				160	200
Accounts payable and accrued liabilities				(327)	390
Deferred revenue				(13)	$ 118
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Accounts receivable	$ 1,709			1,709		3,629
Inventory	336			336		504
Accrued liabilities	1,398			1,398		1,672
Deferred revenue	2,891			2,891		2,841
Deferred revenue, non-current	581			581		534
Accumulated deficit	(114,614)			(114,614)		(111,074)
Total net sales				5,946
Cost of product sales				736
Loss from operations				(4,252)
Net loss				$ (3,540)
Earnings Per Share, Basic, Total				$ (0.21)
Earnings Per Share, Diluted, Total				$ (0.25)
Accounts receivable				$ 1,919
Inventory				166
Accounts payable and accrued liabilities				(459)
Deferred revenue				128
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Accounts receivable	(315)			(315)		530
Inventory	19			19		(25)
Accrued liabilities	(1,267)			(1,267)		1,166
Deferred revenue	2,829			2,829		(2,766)
Deferred revenue, non-current	581			581		(534)
Accumulated deficit	$ (2,439)			(2,439)		$ 2,639
Total net sales				205
Cost of product sales				6
Loss from operations				199
Net loss				$ 199
Earnings Per Share, Basic, Total		$ 0.01
Earnings Per Share, Diluted, Total				$ 0.01
Accounts receivable				$ (215)
Inventory				6
Accounts payable and accrued liabilities				(132)
Deferred revenue				$ 141

Note 8 - Adoption of ASC Topi48

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers" - Changes in Assets and Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Contract Liabilities: Deferred Revenue, beginning of the period	$ 75
Contract Liabilities: Deferred Revenue, additions
Contract Liabilities: Deferred Revenue, deductions	(13)
Contract Liabilities: Deferred Revenue, end of the period	62
Contract Liabilities: Accrued Liabilities, beginning of the period	1,458
Contract Liabilities: Accrued Liabilities, additions	6,516
Contract Liabilities: Accrued Liabilities, deductions	(6,396)
Contract Liabilities: Accrued Liabilities, end of the period	1,487
Contract Liabilities, beginning of the period	1,533
Contract Liabilities, additions	6,516
Contract Liabilities, deductions	(6,409)
Contract Liabilities, end of the period	$ 1,640

Note 8 - Adoption of ASC Topi49

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers" - Total Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Total sales, net	$ 2,794	$ 4,122	$ 5,741	$ 7,823
Transferred over Time [Member]
Total sales, net			1,426
Transferred at Point in Time [Member]
Total sales, net			$ 4,315

Note 8 - Adoption of ASC Topi50

Note 8 - Adoption of ASC Topic 606, "Revenue From Contracts With Customers" - Revenue Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Total revenue recognized	$ 121	$ 317	$ 134	$ 397
Technology Service [Member]
Total revenue recognized		28	13	35
Product [Member]
Total revenue recognized	$ 121	$ 289	$ 121	$ 362

Note 9 - Commitments and Cont51

Note 9 - Commitments and Contingencies (Details Textual)	Aug. 24, 2016ft²	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jul. 11, 2016ft²
Area of Property in Sublease Agreement | ft²						16,465
Operating Leases, Rent Expense, Total		$ 96,000	$ 97,000	$ 193,000	$ 196,000
Master Fleet Lease Agreement [Member]
Number of Vehicles Leased				54
Lessee, Operating Lease, Term of Contract		3 years		3 years
Lease Agreement, Monthly Payment		$ 14,000		$ 14,000
Lease Agreement, Management Fee Per Vehicle		15		15
Lease Agreement, Initial Payment Per Vehicle		3,000		3,000
Operating Leases, Rent Expense, Net, Total		$ 31,000	$ 39,000	$ 62,000	$ 56,000
KBSIII Towers [Member]
Lessee Leasing Arrangements, Operating Leases, Square Feet of Property | ft²	7,799
Lessee, Operating Lease, Renewal Term	5 years
Lessee Leasing Arrangements, Operating Leases, Earliest Period Prior to Expiration of Current Term to Renew Lease	1 year
Lessee Leasing Arrangements, Operating Leases, Latest Period Prior to Expiration of Current Term to Renew Lease	270 days

Note 10 - Warrant Liability (De

Note 10 - Warrant Liability (Details Textual) - USD ($)	Aug. 01, 2016	May 05, 2016	Apr. 04, 2016	Feb. 16, 2016	Oct. 27, 2015	Oct. 27, 2015	Oct. 22, 2015	Jul. 31, 2011	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Sep. 29, 2016	Sep. 28, 2016	Aug. 31, 2016	May 31, 2016	Feb. 29, 2016	Mar. 31, 2015	Jan. 05, 2012
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued								139,520
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 33.25				$ 1.81		$ 1.81	$ 3.15	$ 19.50
Minimum Common Stock Closing Bid Price Per Share																					$ 66.50
Stock Issued During Period, Shares, New Issues				1,518,567
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										363,523	3,613,284						1,047,121	2,039,530
Warrants and Rights Outstanding												$ 785,000		$ 1,489,000
Class of Warrant or Right, Exercised During Period										363,523	3,613,284
Proceeds from Warrant Exercises										$ 900,000	$ 6,600,000		$ 38,000
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.91
Warrant Expiration Term			4 years
Stock Issued During Period, Shares, New Issues	2,094,241	4,079,058	6,173,299
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,047,121	2,039,530	3,086,651
Underwriting Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5	$ 5
Warrant Expiration Term					5 years
Stock Issued During Period, Shares, New Issues						492,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					442,802	442,802
Proceeds from Issuance of Stock and Warrants					$ 2,100,000
Warrants and Rights Outstanding					1,300,000	$ 1,300,000
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues				696,590
Short-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 15
Warrants and Rights Outstanding												130,000
Short-term Warrants [Member] | Private Placement [Member]
Warrant Expiration Term							1 year 90 days
Long-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 16.25
Warrants and Rights Outstanding												$ 136,000
Long-term Warrants [Member] | Private Placement [Member]
Warrant Expiration Term							5 years
The 2011 and March 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 5
Warrants to be Exercised at Lower Price Stock Price Trigger							5
Class of Warrant or Right Price Protection Provision Exchangeable Securities Exercise Price Trigger							$ 5
Warrants and Rights Outstanding					$ 1,800,000	$ 1,800,000
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										363,523	3,613,284
Class of Warrant or Right, Exercised During Period										363,523	3,613,284
Proceeds from Warrant Exercises										$ 900,000	$ 6,900,000
Warrant Liabilities, Fair Value Disclosure										500,000	1,600,000
Fair Market Value of Warrants Transferred to Equity Upon Exercise										$ 500,000	$ 1,600,000
July 2011, March 2015, and October 2015 Warrants [Member] | Mr. Fu [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																			$ 1.81
March 2015 Short-term and Long-term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									21,000				21,000
Class of Warrant or Right, Exercised During Period									21,000
Proceeds from Warrant Exercises									$ 38,000
Warrant Liabilities, Fair Value Disclosure									58,000				$ 58,000
Fair Market Value of Warrants Transferred to Equity Upon Exercise									$ 58,000

Note 10 - Warrant Liability - T

Note 10 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details)	Jun. 30, 2018	Dec. 31, 2017
Measurement Input, Price Volatility [Member] | The 2011 Warrants [Member]
Warrants assumptions	66	91
Measurement Input, Price Volatility [Member] | Short-term Warrants [Member]
Warrants assumptions	66	91
Measurement Input, Price Volatility [Member] | Long-term Warrants [Member]
Warrants assumptions	66	91
Measurement Input, Price Volatility [Member] | October 2015 Warrants [Member]
Warrants assumptions	73	90
Measurement Input, Expected Term [Member] | The 2011 Warrants [Member]
Warrants assumptions	1.68	2.18
Measurement Input, Expected Term [Member] | Short-term Warrants [Member]
Warrants assumptions	1.68	2.18
Measurement Input, Expected Term [Member] | Long-term Warrants [Member]
Warrants assumptions	1.68	2.18
Measurement Input, Expected Term [Member] | October 2015 Warrants [Member]
Warrants assumptions	2.33	2.83
Measurement Input, Risk Free Interest Rate [Member] | The 2011 Warrants [Member]
Warrants assumptions	2.46	1.91
Measurement Input, Risk Free Interest Rate [Member] | Short-term Warrants [Member]
Warrants assumptions	2.46	1.91
Measurement Input, Risk Free Interest Rate [Member] | Long-term Warrants [Member]
Warrants assumptions	2.46	1.91
Measurement Input, Risk Free Interest Rate [Member] | October 2015 Warrants [Member]
Warrants assumptions	2.56	1.96
Measurement Input, Expected Dividend Rate [Member] | The 2011 Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Expected Dividend Rate [Member] | Short-term Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Expected Dividend Rate [Member] | Long-term Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Expected Dividend Rate [Member] | October 2015 Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Share Price [Member] | The 2011 Warrants [Member]
Warrants assumptions	1.42	2.72
Measurement Input, Share Price [Member] | Short-term Warrants [Member]
Warrants assumptions	1.13	2.42
Measurement Input, Share Price [Member] | Long-term Warrants [Member]
Warrants assumptions	1.42	2.72
Measurement Input, Share Price [Member] | October 2015 Warrants [Member]
Warrants assumptions	1.58	2.86

Note 10 - Warrant Liability - O

Note 10 - Warrant Liability - Outstanding Warrant Liability (Details) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Shares (in shares)	544	544
Warrant liability	$ 785	$ 1,489
The 2011 Warrants [Member]
Shares (in shares)	49
Warrant liability	$ 70
Long-term Warrants [Member]
Shares (in shares)	96
Warrant liability	$ 136
Short-term Warrants [Member]
Shares (in shares)	115
Warrant liability	$ 130
October 2015 Warrants [Member]
Shares (in shares)	284
Warrant liability	$ 449
July 2011, Long-term, Short-term, and October 2015 Warrants [Member]
Shares (in shares)	544
Warrant liability	$ 785

Note 11 - Stockholders' Equit55

Note 11 - Stockholders' Equity (Deficit) (Details Textual)	Sep. 29, 2016USD ($)$ / shares	Aug. 01, 2016USD ($)shares	May 05, 2016USD ($)shares	Apr. 04, 2016USD ($)$ / sharesshares	Feb. 16, 2016USD ($)$ / sharesshares	Dec. 18, 2015	Dec. 11, 2015	Jun. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)shares	Sep. 30, 2016USD ($)shares	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Jun. 04, 2018shares	Jun. 03, 2018shares	Dec. 31, 2017$ / sharesshares	Sep. 30, 2017shares	Sep. 28, 2016$ / shares	Aug. 31, 2016shares	May 31, 2016shares	Feb. 29, 2016$ / shares	Jul. 31, 2011$ / shares
Common Stock, Shares Authorized								50,000,000					50,000,000		50,000,000	240,000,000	240,000,000
Preferred Stock, Shares Authorized								5,000,000					5,000,000				5,000,000	5,000,000
Preferred Stock, Shares Outstanding, Ending Balance								0					0				0
Stock Issued During Period, Shares, New Issues					1,518,567
Stock Issued During Period, Value, New Issues | $					$ 2,800,000
Class of Warrant or Right, Exercise Price, Discount from Market Price	16.00%
Private Placement, Commission Percentage				6.00%	6.00%						6.00%	6.00%
Common Stock, Par or Stated Value Per Share | $ / shares								$ 0.01					$ 0.01				$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											363,523	3,613,284								1,047,121	2,039,530
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.15							$ 1.81					$ 1.81				$ 1.81		$ 19.50				$ 33.25
Proceeds from Warrant Exercises | $											$ 900,000	$ 6,600,000		$ 38,000
Class of Warrant or Right, Exercised During Period											363,523	3,613,284
Warrants Exercised, Commission Paid | $											$ 32,000	$ 338,000
Fair Value Adjustment of Warrants | $								$ (490,000)		$ (15,000)			$ (704,000)	$ 220,000
General and Administrative Expense [Member]
Fair Value Adjustment of Warrants | $	$ 270,000
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											363,523	3,613,284
Proceeds from Warrant Exercises | $											$ 900,000	$ 6,900,000
Class of Warrant or Right, Exercised During Period											363,523	3,613,284
Mr. Fu [Member]
Stock Issued During Period, Shares, New Issues					696,590
Shares Issued, Price Per Share | $ / shares					$ 1.81
Class of Warrant or Right, Exercise Price, Discount from Market Price					5.00%
Mr. Fu [Member] | July 2011, March 2015, and October 2015 Warrants [Member]
Shares Issued, Price Per Share | $ / shares																						$ 1.81
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																						$ 1.81
Pioneer Pharma Co. [Member]
Stock Issued During Period, Shares, New Issues					696,590
Shares Issued, Price Per Share | $ / shares					$ 1.91
Mr. Sieczkarek [Member]
Stock Issued During Period, Shares, New Issues					125,387
Shares Issued, Price Per Share | $ / shares					$ 1.91
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		2,094,241	4,079,058	6,173,299
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,047,121	2,039,530	3,086,651
Sale of Stock, Consideration Received on Transaction | $		$ 4,000,000	$ 7,800,000	$ 11,800,000
Warrant Expiration Term				4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.91
Number of Sequential Trading Days				5 days
Private Placement [Member] | Minimum [Member]
Common Stock, Closing Price | $ / shares				$ 4
Private Placement [Member] | China Kington Asset Management Co. Ltd. [Member]
Private Placement, Commission Percentage									6.00%
Payments of Stock Issuance Costs | $				$ 618,000	$ 155,000				$ 359,040
Warrants Exercised, Commission Paid | $									$ 34,000
Private Placement [Member] | OP Financial Investments Limited [Member]
Stock Issued During Period, Shares, New Issues									1,700,000
Stock Issued During Period, Value, New Issues | $									$ 5,984,000
Common Stock, Par or Stated Value Per Share | $ / shares									$ 0.01
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						25	25

Note 11 - Stockholders' Equit56

Note 11 - Stockholders' Equity (Deficit) - Outstanding Warrants (Details) - $ / shares	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2018
Warrants outstanding (in shares)			544,000
Warrants outstanding, weighted average exercise price (in dollars per share)			$ 1.81
Warrants granted (in shares)
Warrants granted, weighted average exercise price (in dollars per share)
Warrants exercised (in shares)	(363,523)	(3,613,284)
Warrants exercised, weighted average exercise price (in dollars per share)
Warrants expired (in shares)
Warrants expired, weighted average exercise price (in dollars per share)
Warrants outstanding (in shares)			544,000
Warrants outstanding, weighted average exercise price (in dollars per share)			$ 1.81

Note 12 - Equity-based Compen57

Note 12 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands	Mar. 21, 2018	Mar. 20, 2018	May 26, 2016	Mar. 30, 2015	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2011	Jan. 31, 2010	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2007
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period														0	4,000	0
Proceeds from Stock Options Exercised														$ 0	$ 11	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value															$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															814,000
Allocated Share-based Compensation Expense, Total													$ 154	496	$ 340	1,689
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense													0	0	$ 0	$ 0
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															809,000	1,292,000
Allocated Share-based Compensation Expense, Total													148	442	$ 327	$ 1,600
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period															12,000	0
Mr. Liu [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	3 years	90 days
Allocated Share-based Compensation Expense, Total															$ 26
Nonemployees [Member]
Allocated Share-based Compensation Expense, Total													6	$ 53	$ 13	$ 89
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued															5,000	85,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares																31,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															4 years
Employee Stock Options and RSUs [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total													$ 2,300		$ 2,300
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition															3 years 62 days
The 2007 Omnibus Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance																			40,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Annual Increase in Shares Authorized																		40,000
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock																	4.00%	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			1,124,826	82,461				32,646	59,157	40,000	37,427	37,207
Increase (Decrease) in Number of Shares Available for Grant						610,774	139,449
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum															10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															4 years
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															100.00%
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															110.00%
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
The 2017 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock													4.00%		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					615,392
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized													2,318,486		2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant													1,383,470		1,383,470
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum															10.00%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															100.00%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															110.00%
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															5 years

Note 12 - Equity-based Compen58

Note 12 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Outstanding (in shares)		2,960,000
Outstanding, weighted-average exercise price (in dollars per share)		$ 5.16
Outstanding, weighted-average remaining contractual life (Year)		8 years 219 days		8 years 219 days
Outstanding, aggregate intrinsic value		$ 412		$ 2,586
Options granted (in shares)		814,000
Options granted, weighted-average exercise price (in dollars per share)		$ 2.21
Options exercised (in shares)	0	(4,000)	0
Options exercised, weighted-average exercise price (in dollars per share)		$ 2.35
Options forfeited/cancelled (in shares)		(593,000)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)		$ 5.18
Outstanding (in shares)		3,189,000		2,960,000
Outstanding, weighted-average exercise price (in dollars per share)		$ 4.39		$ 5.16
Vested and expected to vest (in shares)		2,829,000
Vested and expected to vest, weighted-average exercise price (in dollars per share)		$ 4.62
Vested and expected to vest, weighted-average remaining contractual life (Year)		8 years 219 days
Vested and expected to vest, aggregate intrinsic value		$ 362
Vested (in shares)		1,524,000
Vested, weighted-average exercise price (in dollars per share)		$ 6.42
Vested, weighted-average remaining contractual life (Year)		7 years 255 days
Exercisable (in shares)		1,524,000
Exercisable, weighted-average exercise price (in dollars per share)		$ 6.42
Exercisable, weighted-average remaining contractual life (Year)		7 years 255 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)		12,000
Restricted stock units granted, weighted-average exercise price (in dollars per share)
Restricted stock units vested (in shares)
Restricted stock units vested, weighted-average exercise price (in dollars per share)
Restricted stock units cancelled (in shares)

Note 12 - Equity-based Compen59

Note 12 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Expected price volatility	88.86%	87.72%
Expected term (Year)	5 years 354 days	6 years 328 days
Risk-free interest rate	2.71%	2.11%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 1.64	$ 2.25

Note 12 - Equity-based Compen60

Note 12 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Non-employees (Details) - Nonemployees [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Expected price volatility	84.83%	87.42%
Expected term (Year)	10 years	10 years
Risk-free interest rate	2.81%	2.27%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 1.86	$ 2.38

Note 12 - Equity-based Compen61

Note 12 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stock-based compensation expense	$ 154	$ 496	$ 340	$ 1,689
Research and Development Expense [Member]
Stock-based compensation expense	12	28	19	49
Selling and Marketing Expense [Member]
Stock-based compensation expense	45	57	79	94
General and Administrative Expense [Member]
Stock-based compensation expense	$ 97	$ 411	$ 242	$ 1,546

Note 13 - Employee Benefit Pl62

Note 13 - Employee Benefit Plan (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 14 - Related Party Trans63

Note 14 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Accounts Receivable, Related Parties	$ 0		$ 0		$ 0
Related-party Commission Fees [Member] | China Kingston [Member]
Related Party Transaction, Expenses from Transactions with Related Party	0		359	$ 0
Amortization Revenue [Member] | Neutrophase [Member]
Other Income	$ 0	$ 9	$ 13	$ 15